<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-133545" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aleem</surname>
            <given-names>Abdul</given-names>
          </name>
          <aff>Lehigh Valley Health Network, Allentown, USA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nadeem</surname>
            <given-names>Ahmed J.</given-names>
          </name>
          <aff>Lehigh Valley Health Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdul Aleem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmed Nadeem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-133545.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to cause significant morbidity and mortality worldwide, with many&#x000a0;nations enduring multiple outbreaks of this viral illness. Besides the importance of infection control measures to prevent or decrease the transmission of SARS-CoV-2, the most crucial step to contain this global pandemic is to vaccinate individuals to prevent SARS-CoV-2 infection in communities across the world. Many vaccines have been developed at an unprecedented speed using distinctive technologies to prevent COVID-19. Vaccination triggers the immune system resulting in the production of neutralizing antibodies against SARS-CoV-2. Four vaccines, namely the BNT162b2, mRNA-1273, Ad26.COV2.S, and ChAdOx1 nCoV-19 have been approved to prevent COVID-19 in many nations&#x000a0;worldwide, including the United States. The&#x000a0;BNT162b2, mRNA-1273 have been approved by the U.S. FDA and the&#x000a0;Ad26.COV2.S has received Emergency Use Authorization. One exception is the ChAdOx1 nCoV-19 vaccine, which has not yet received a EUA or approval from the U.S. Food and Drug Administration (FDA) for use in the U.S. The BNT162b2 and mRNA-1273 vaccines are both mRNA-based, while the Ad26.COV2. S and ChAdOx1 nCoV-19 vaccines incorporate replication-incompetent adenoviral vectors in them.</p>
        <p>In late February 2021, a new clinical syndrome characterized by thrombosis at atypical sites combined with thrombocytopenia was observed in multiple patients days after vaccination with the ChAdOx1 nCoV-19 vaccine.<xref ref-type="bibr" rid="article-133545.r1">[1]</xref>&#x000a0;In April 2021, similar clinical sequelae were reported in patients after vaccination with the Ad26.COV2. S vaccine.<xref ref-type="bibr" rid="article-133545.r2">[2]</xref> Preceding the approval of these vaccines, the clinical constellation of this new syndrome was not observed in clinical trials of the ChAdOx1 nCoV-19 vaccine, and a single case was observed in the Ad26.COV2. S vaccine trial recipient.<xref ref-type="bibr" rid="article-133545.r3">[3]</xref><bold>&#x000a0;</bold>Furthermore, the incidence of major adverse effects has remained exceptionally low following the vaccination of more than 400 million people worldwide.<xref ref-type="bibr" rid="article-133545.r4">[4]</xref>&#x000a0;This novel clinical syndrome demonstrated striking similarities to heparin-induced thrombocytopenia; however, in the absence of prior heparin exposure was named vaccine-induced immune thrombotic thrombocytopenia (VITT).&#x000a0;It is also known as&#x000a0;vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) in some European&#x000a0;nations and Canada.&#x000a0;Conversely, in millions of doses of BNT162b2 or mRNA-1273 vaccines administered so far, this clinical syndrome has not been reported.&#x000a0;Due to the concern of VITT associated with the Ad26.COV2. S vaccine, the FDA modified the EUA and recommends limiting the use of this vaccine only to individuals &#x0003e; 18 years of age who are otherwise ineligible to receive any other FDA-approved vaccines due to anaphylaxis to mRNA vaccines or its components or are unable/unwilling to receive any other vaccine.</p>
        <p>Per the American Society of Hematology, vaccine-induced immune thrombotic thrombocytopenia (VITT) is defined as a clinical syndrome characterized by all of the below described abnormal laboratory and radiologic abnormalities occurring in individuals 4 to 42 days after vaccination with Ad26.COV2. S or ChAdOx1 nCoV-19 vaccines.</p>
        <list list-type="bullet">
          <list-item>
            <p>Development of thrombosis at uncommon sites includes cerebral venous sinus thrombosis (CSVT)/splanchnic venous thrombosis</p>
          </list-item>
          <list-item>
            <p>Mild to severe thrombocytopenia. However, a normal platelet count does not exclude the possibility of this syndrome in its early stages</p>
          </list-item>
          <list-item>
            <p>Positive antibodies against platelet factor 4(PF4) identified by enzyme-linked immunosorbent assay (ELISA) assay</p>
          </list-item>
          <list-item>
            <p>Significantly elevated D-dimer ( &#x0003e; 4 times ULN)</p>
          </list-item>
        </list>
        <p>This review article aims to describe the etiology, epidemiology, pathophysiology, clinical features, diagnosis, and management of COVID-19 vaccine-induced thrombotic immune thrombocytopenia based on the latest available published literature.</p>
      </sec>
      <sec id="article-133545.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Several cases of uncommon thrombotic events associated in combination with thrombocytopenia were observed in patients who were vaccinated with ChAdOx1 nCoV-19 vaccines.<xref ref-type="bibr" rid="article-133545.r5">[5]</xref><xref ref-type="bibr" rid="article-133545.r6">[6]</xref>&#x000a0;Although a causal relationship has not been well defined, the increased reporting in the UK as well as in Europe of CVST and thrombocytopenia in individuals vaccinated with ChAdOx1 nCoV-19 compared to&#x000a0;the absence of cases in individuals immunized with BNT162b2 or mRNA-1273 vaccines proved to be a strong indication that this syndrome was potentially associated with the ChAdOx1 nCoV-19 vaccine.<xref ref-type="bibr" rid="article-133545.r7">[7]</xref>&#x000a0;</p>
        <p>Due to the rarity of this clinical syndrome among vaccinated individuals, there is currently no evidence suggesting that individuals with prior history of thrombosis or risk factors for developing thrombosis are at increased risk of developing VITT. It is also unclear at this time as to why this immune-mediated thrombosis manifests mainly in the cerebral vessels and splanchnic circulation.<xref ref-type="bibr" rid="article-133545.r8">[8]</xref></p>
      </sec>
      <sec id="article-133545.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of VITT is extremely low. The true causal relationship between this novel clinical entity and the vaccines has not been established yet but is considered plausible based on a statement issued by&#x000a0; The World Health Organization(WHO) on 7 April 2021. As per the European Medicines Agency (EMA), the incidence of VITT&#x000a0; after vaccination with ChAdOx1 nCoV-19&#x000a0;is estimated to be between 1 in 125,000 and 1 in 1 million. Notably, more than 80%&#x000a0;of the patients in reported cases of VITT were females and aged between 20 to 55 years of age.</p>
        <p>After a brief pause in the administration of the ChAdOx1 nCoV-19, the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) completed internal reviews and favored resuming vaccination with this vaccine, emphasizing that the benefits of the vaccine outweigh the risk of developing thrombosis. However, the causal relationship was not described by&#x000a0;either agency. Recently, of the nearly 6.8 million doses of Ad26.COV2. S, a small number of female patients aged between 18 and 48 developed a similar clinical constellation of cerebral venous sinus thrombosis and thrombocytopenia that occurred 6 to 13 days after vaccination<bold>.</bold><xref ref-type="bibr" rid="article-133545.r2">[2]</xref><xref ref-type="bibr" rid="article-133545.r3">[3]</xref>&#x000a0;The CDC and the FDA have recommended a pause in vaccination with Ad26.COV2. S vaccine in the U.S. to allow for further review of this vaccine.</p>
      </sec>
      <sec id="article-133545.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of vaccine-induced thrombotic thrombocytopenia is not known at this time. However, given its clinical presentation and biochemical similarities to heparin-induced thrombocytopenia, which is a prothrombotic and potentially life-threatening condition, a similar immune-mediated response induced by these adenoviral vector vaccines has been postulated as immune complexes with a mixture of antibody specificities similar to HIT was noted in the serum of patients who developed this syndrome.<xref ref-type="bibr" rid="article-133545.r6">[6]</xref><xref ref-type="bibr" rid="article-133545.r1">[1]</xref>&#x000a0;</p>
        <p>Based on a report by the Society of Thrombosis and Haemostasis Research (GTH), it has been hypothesized that postvaccination antibodies are formed against platelet antigens as a part of the immune stimulation process. These antibodies trigger massive platelet activation against PF4, resulting in immune thrombotic thrombocytopenia.<xref ref-type="bibr" rid="article-133545.r8">[8]</xref>&#x000a0;Cross-reaction between the vaccine and platelets or PF4 has also been highlighted as a potential contributing factor in the pathogenesis of this syndrome especially knowing that adenovirus can bind to platelets resulting in platelet activation. Further&#x000a0;clinical studies are needed to determine the pathophysiological mechanism of this new syndrome precisely.<xref ref-type="bibr" rid="article-133545.r6">[6]</xref></p>
      </sec>
      <sec id="article-133545.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A detailed clinical history regarding the onset and duration of symptoms, vaccination history that includes exact timing, drug history, and particularly recent exposure to heparin should be obtained by treating providers.</p>
        <p>
<bold>Pertinent Clinical Features Concerning VITT</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>New neurologic symptoms such as severe, recurrent, or persistent headaches, seizures, blurry or double vision, focal weakness, aphasia</p>
          </list-item>
          <list-item>
            <p>Severe abdominal pain or persistent nausea and vomiting</p>
          </list-item>
          <list-item>
            <p>Backache</p>
          </list-item>
          <list-item>
            <p>Shortness of breath</p>
          </list-item>
          <list-item>
            <p>Chest pain</p>
          </list-item>
          <list-item>
            <p>Leg pain and or swelling</p>
          </list-item>
          <list-item>
            <p>Petechiae or purpura</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133545.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Laboratory Assessment in VITT</bold>
</p>
        <p>Based on the treatment guidelines by the British Society of Haematology (BSH), Society of Thrombosis and Haemostasis Research (GTH), and American Society of Hematology (ASH), patients suspected of VITT should undergo&#x000a0;initial laboratory workup and imaging modalities as described below.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>CBC with platelet count and peripheral blood smear</bold>
<list list-type="bullet"><list-item><p>Typical platelet nadir ranging from 9,000 to 107,000 have been reported.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Coagulation panel </bold>(PT/INR and aPTT)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Fibrinogen</bold>
<list list-type="bullet"><list-item><p>Typically, low levels of fibrinogen have been noted in VITT.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>D-dimer level</bold>
<list list-type="bullet"><list-item><p>Markedly elevated D-dimer levels( &#x0003e; 4 times ULN) were observed in most cases.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Fibrinogen</bold>
<list list-type="bullet"><list-item><p>Typically, low levels of fibrinogen have been noted in VITT.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>PF4-heparin ELISA</bold>
<list list-type="bullet"><list-item><p>GTH recommends this as the first test in their diagnostic algorithm.<xref ref-type="bibr" rid="article-133545.r8">[8]</xref></p></list-item><list-item><p>In most reported cases with no heparin exposure, the serum demonstrated vigorous reactivity on the PF4&#x02013;heparin ELISA.</p></list-item><list-item><p>If negative, VITT can be ruled out as almost all reported VITT had positive PF4-heparin ELISA results.</p></list-item><list-item><p>If low positive, patients should undergo the confirmatory PF4 platelet activation assay.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>PF4-dependent platelet activation assay</bold>
<list list-type="bullet"><list-item><p>Serotonin release assay</p></list-item><list-item><p>P-selectin expression assay</p></list-item><list-item><p>Heparin-induced platelet activation (HIPA)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pertinent Imaging Studies</bold>
</p>
        <p>Clinicians should consider the following studies:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Intracranial imaging</bold>&#x000a0;-&#x000a0; this is focused on evaluating for cerebral sinus venous thrombosis (CSVT) with either magnetic resonance imaging (MRI) venogram or computed tomography (CT).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Transabdominal and Transthoracic imaging</bold>&#x000a0;focused on evaluating for splanchnic thrombosis and/or pulmonary emboli with computed tomography (CT) or magnetic resonance imaging (MRI) venogram.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Duplex Ultrasound&#x000a0;</bold>of the lower extremities&#x000a0;is another option if clinically indicated for evaluating deep vein thrombosis (DVT).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133545.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The American Society of Hematology treatment recommendations for VITT is similar to that of severe HIT in patients presenting with thrombocytopenia, documented evidence or suspicion of thrombosis, and positive or pending PF4-heparin ELISA. Management is based on the treatment guidelines from the British Society of Haematology (BSH), the Society of Thrombosis and Haemostasis Research (GTH), and the American Society of Hematology (ASH).<xref ref-type="bibr" rid="article-133545.r8">[8]</xref>&#x000a0;Their recommendations are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Urgent administration of&#x000a0;<bold>high dose intravenous immunoglobulin (IVIG)</bold>&#x000a0;1 gram/kg (ideal body weight) daily for two days</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Evaluation for HIT/VITT should be performed before administering IVIG to prevent false-negative test results due to potential interference of IVIG with ELISA and platelet activation assays.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Given its close resemblance to HIT, the use of heparin may be harmful, and&#x000a0;<bold>non-heparin anticoagulants</bold>&#x000a0;should be considered, such as:</p>
          </list-item>
        </list>
        <p>
<list list-type="bullet"><list-item><p><bold>Direct thrombin inhibitors</bold>: Argatroban or bivalirudin</p></list-item></list>
</p>
        <p>
<list list-type="bullet"><list-item><p><bold>Direct oral anti-Xa inhibitors without heparin bridge</bold>: Edoxaban, apixaban, dabigatran, or rivaroxaban</p></list-item></list>
</p>
        <p>
<list list-type="bullet"><list-item><p><bold>Low molecular weight heparinoid devoid of heparin</bold>: Danaparoid</p></list-item></list>
</p>
        <p>
<list list-type="bullet"><list-item><p><bold>Selective factor Xa inhibitor</bold>: Fondaparinux</p></list-item></list>
</p>
        <p>
<bold>Other Treatment Recommendations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hematology specialist consultation must be sought as early as possible.</p>
          </list-item>
          <list-item>
            <p>IVIG and non-heparin-based anticoagulation should be initiated if there is a high suspicion for the diagnosis of VITT and&#x000a0;PF4-ELISA results are pending.</p>
          </list-item>
          <list-item>
            <p>Platelet transfusions should be avoided and should be considered only if clinically indicated and at the advice of a hematologist.</p>
          </list-item>
          <list-item>
            <p>Fibrinogen must be corrected with fibrinogen concentrate or cryoprecipitate to maintain a fibrinogen level of &#x0003e;1.5 g/L.</p>
          </list-item>
          <list-item>
            <p>All forms of heparin that include heparin-based flushes must be avoided until VITT is ruled out.</p>
          </list-item>
          <list-item>
            <p>Patients should be transferred to a tertiary care center once the diagnosis of VITT is confirmed.</p>
          </list-item>
          <list-item>
            <p>Both the BSH and ASH recommend continuing systemic anticoagulation for a minimum of three months in patients with documented thrombosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133545.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Heparin-induced thrombocytopenia (HIT)</p>
          </list-item>
          <list-item>
            <p>Thrombotic thrombocytopenic purpura (TTP)</p>
          </list-item>
          <list-item>
            <p>Hereditary thrombophilia</p>
          </list-item>
          <list-item>
            <p>Acquired thrombophilia</p>
          </list-item>
          <list-item>
            <p>Drug-induced (e.g., pentosan polysulfate, hypersulfated chondroitin sulfate)</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia reactive to an acute medical condition</p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenic purpura (ITP)</p>
          </list-item>
          <list-item>
            <p>Post vaccine ITP</p>
          </list-item>
          <list-item>
            <p>Antiphospholipid syndrome</p>
          </list-item>
          <list-item>
            <p>Atypical hemolytic uremic syndrome (HUS)</p>
          </list-item>
          <list-item>
            <p>Paroxysmal nocturnal hematuria (PNH)</p>
          </list-item>
          <list-item>
            <p>Malignant hematological disorders</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133545.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Considering this newly described syndrome is evolving, the prognosis of vaccine-induced thrombotic thrombocytopenia is not known. This estimated mortality rate related to the use of ChAdOx1 nCoV-19 was calculated to be low at one death in a million.<xref ref-type="bibr" rid="article-133545.r9">[9]</xref>&#x000a0;However, considering thrombosis more commonly involves atypical sites such as cerebral veins, rapid identification of this syndrome is crucial to prevent long-term morbidity and mortality.</p>
      </sec>
      <sec id="article-133545.s10" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Thrombotic complications:
<list list-type="bullet"><list-item><p>Cerebral venous sinus thrombosis</p></list-item><list-item><p>Splanchnic vein thrombosis</p></list-item><list-item><p>Pulmonary embolism</p></list-item><list-item><p>Deep vein thrombosis</p></list-item><list-item><p>Arterial thrombosis</p></list-item><list-item><p>Ophthalmic vein thrombosis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Intraparenchymal brain hemorrhage</p>
          </list-item>
          <list-item>
            <p>Ischemic stroke</p>
          </list-item>
          <list-item>
            <p>Disseminated intravascular coagulation (DIC)<xref ref-type="bibr" rid="article-133545.r1">[1]</xref><xref ref-type="bibr" rid="article-133545.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133545.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <list list-type="bullet">
          <list-item>
            <p>In most individuals, the risk of contracting COVID-19 and the risk of COVID-19-associated thrombosis and associated mortality is far greater than the risk of developing VITT.<xref ref-type="bibr" rid="article-133545.r11">[11]</xref><xref ref-type="bibr" rid="article-133545.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>The overall benefits of vaccination for prevention against COVID-19 must be reiterated.</p>
          </list-item>
          <list-item>
            <p>Adult individuals should be encouraged to speak to their&#x000a0;clinician to discuss the risks and benefits before receiving the vaccination.</p>
          </list-item>
          <list-item>
            <p>Prior to vaccination, individuals should be educated about the clinical symptoms associated with this syndrome and should be advised to seek urgent medical treatment.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133545.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <list list-type="bullet">
          <list-item>
            <p>According to health authorities, vaccination for prevention against COVID-19 is crucial in containing the spread of SARS-CoV-2 and controlling this pandemic.</p>
          </list-item>
          <list-item>
            <p>Given the concern of VITT in individuals vaccinated with the adenoviral vector vaccines(Ad26.COV2.S and ChAdOx1 nCoV-19), healthcare providers, including emergency medicine physicians, primary care clinicians should maintain a high index of suspicion in patients presenting with symptoms on laboratory abnormalities suggestive of VITT as early recognition and management of this syndrome can prevent catastrophic complications.</p>
          </list-item>
          <list-item>
            <p>The recognition and management of VITT require an interprofessional team approach that includes hematology specialist physicians, nurses, laboratory staff, and pharmacists.</p>
          </list-item>
          <list-item>
            <p>Pharmacists should assist clinicians with different non-heparin anticoagulation formulations available in the formulary. Nurses taking care of patients should be aware of the syndrome&#x02019;s close resemblance with heparin-induced thrombocytopenia.</p>
          </list-item>
          <list-item>
            <p>They should receive education regarding avoiding heparin flushes and detailed instructions about weight-based administration of IVIG.</p>
          </list-item>
          <list-item>
            <p>There should be close communication between the ordering clinician, the pharmacist, the nurse, and healthcare providers to keep themselves updated with the latest literature regarding this evolving new syndrome.</p>
          </list-item>
          <list-item>
            <p>Such a holistic approach would lead to early identification of this rare potential life-threatening syndrome and early treatment, which would significantly impact the morbidity and mortality associated with this syndrome.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133545.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=133545&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=133545">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/133545/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=133545">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-133545.s14">
        <title>References</title>
        <ref id="article-133545.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Weisser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kyrle</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Eichinger</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jun</month>
            <day>03</day>
            <volume>384</volume>
            <issue>22</issue>
            <fpage>2092</fpage>
            <page-range>2092-2101</page-range>
            <pub-id pub-id-type="pmid">33835769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muir</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Kallam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koepsell</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Gundabolu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>May</month>
            <day>20</day>
            <volume>384</volume>
            <issue>20</issue>
            <fpage>1964</fpage>
            <page-range>1964-1965</page-range>
            <pub-id pub-id-type="pmid">33852795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Douoguih</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>May</month>
            <day>20</day>
            <volume>384</volume>
            <issue>20</issue>
            <fpage>1965</fpage>
            <page-range>1965-1966</page-range>
            <pub-id pub-id-type="pmid">33861522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jun</month>
            <day>10</day>
            <volume>384</volume>
            <issue>23</issue>
            <fpage>2254</fpage>
            <page-range>2254-2256</page-range>
            <pub-id pub-id-type="pmid">33861524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Poles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldblatt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kotoucek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lester</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jun</month>
            <day>10</day>
            <volume>384</volume>
            <issue>23</issue>
            <fpage>2202</fpage>
            <page-range>2202-2211</page-range>
            <pub-id pub-id-type="pmid">33861525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schultz</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rvoll</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Michelsen</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Munthe</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lund-Johansen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ahlen</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Wiedmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aamodt</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Skatt&#x000f8;r</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Tj&#x000f8;nnfjord</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Holme</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jun</month>
            <day>03</day>
            <volume>384</volume>
            <issue>22</issue>
            <fpage>2124</fpage>
            <page-range>2124-2130</page-range>
            <pub-id pub-id-type="pmid">33835768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunter</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Thrombosis after covid-19 vaccination.</article-title>
            <source>BMJ</source>
            <year>2021</year>
            <month>Apr</month>
            <day>14</day>
            <volume>373</volume>
            <fpage>n958</fpage>
            <pub-id pub-id-type="pmid">33853865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oldenburg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klamroth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Albisetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Auer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Korte</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Scharf</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>P&#x000f6;tzsch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.</article-title>
            <source>Hamostaseologie</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>184</fpage>
            <page-range>184-189</page-range>
            <pub-id pub-id-type="pmid">33822348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahase</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>AstraZeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude.</article-title>
            <source>BMJ</source>
            <year>2021</year>
            <month>Apr</month>
            <day>08</day>
            <volume>373</volume>
            <fpage>n931</fpage>
            <pub-id pub-id-type="pmid">33832929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bayas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menacher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christ</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Behrens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>397</volume>
            <issue>10285</issue>
            <fpage>e11</fpage>
            <pub-id pub-id-type="pmid">33864750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133545.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malas</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Naazie</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Elsayed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mathlouthi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marmor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clary</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis.</article-title>
            <source>EClinicalMedicine</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>29</volume>
            <fpage>100639</fpage>
            <pub-id pub-id-type="pmid">33251499</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
